Skip to main content

Phase 3 Readout

NVS: Phase 3 Topline: A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Effica

June 2, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
June 2, 2026
Company
Novartis AG (NVS)
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout

Phase 3 Topline: A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Effica

NVS overview →
Indication
Sjogren Syndrome

Other upcoming events for NVS

Phase 3 ReadoutPhase 3 Topline: PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Cha
Phase 2 StartPhase 2 Start: A Phase IIb Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-range Study to Assess th
Phase 3 ReadoutPhase 3 Topline: A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 V
Phase 3 ReadoutPhase 3 Topline: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase IIIb Study Evalua
Phase 2 StartPhase 2 Start: VEX-AR: Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase 2 Study Evaluating the Efficacy